Reports Q2 revenue $51.2M, consensus $49.6M.Cash, cash equivalents and investments were $186.2 million as of June 30, 2024.”Our solid second quarter performance demonstrates continued TCAR adoption and growth driven by the unwavering dedication of our team,” said Chas McKhann, CEO of Silk Road Medical. “We look forward to continuing our mission as part of Boston Scientific and, together, expanding patient access to our minimally invasive approach to stroke prevention.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILK:
- Silk Road Medical Reports Second Quarter 2024 Financial Results
- Silk Road Medical announces more than 100,000 TCAR procedures performed
- Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
- SILK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Silk Road Medical downgraded to Sell from Buy at Argus